CHINA PHARMA HOLDINGS, INC. Increase (Decrease) in Contract with Customer, Liability
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Increase (Decrease) in Contract with Customer, Liability of $38.03 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-14
- CHINA PHARMA HOLDINGS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $89.41K.
- CHINA PHARMA HOLDINGS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$51.38K.
- CHINA PHARMA HOLDINGS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was -$36.88K.
- CHINA PHARMA HOLDINGS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was -$48.02K, a 318.45% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$53.44K, a 172.50% decline from fiscal 2024.
- CHINA PHARMA HOLDINGS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $73.72K.
- CHINA PHARMA HOLDINGS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$423.26K, a 224.61% decline from fiscal 2022.
- CHINA PHARMA HOLDINGS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $339.66K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $89.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $38.03K 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | -$51.38K 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$53.44K 10-K · filed 2026-04-01 | |||
| 2025-06-30 | -$36.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$84.90K 10-Q · filed 2026-08-14 | $54.42K derived: sum of 3 quarters · filed 2026-08-14 | -$22.32K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$48.02K 10-Q · filed 2026-05-15 | $91.30K derived: sum of 2 quarters · filed 2026-05-15 | $14.55K derived: sum of 3 quarters · filed 2026-05-15 | $3.71K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $139.32K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $62.57K derived: sum of 2 quarters · filed 2026-04-01 | $51.73K derived: sum of 3 quarters · filed 2026-04-01 | $73.72K 10-K · filed 2026-04-01 |
| 2024-09-30 | -$76.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$87.59K derived: sum of 2 quarters · filed 2024-11-13 | -$65.61K 10-Q · filed 2024-11-13 | -$148.46K derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | -$10.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $11.14K 10-Q · filed 2024-08-14 | -$71.71K derived: sum of 3 quarters · filed 2025-05-14 | $46.88K derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | $21.98K 10-Q · filed 2025-05-14 | -$60.87K derived: sum of 2 quarters · filed 2025-05-14 | $57.72K derived: sum of 3 quarters · filed 2025-05-14 | -$9.26K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$82.85K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $35.74K derived: sum of 2 quarters · filed 2025-03-31 | -$31.24K derived: sum of 3 quarters · filed 2025-03-31 | -$423.26K 10-K · filed 2025-03-31 |
| 2023-09-30 | $118.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $51.61K derived: sum of 2 quarters · filed 2024-11-13 | -$340.41K 10-Q · filed 2024-11-13 | $111.61K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$66.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$459.00K 10-Q · filed 2024-08-14 | -$6.98K derived: sum of 3 quarters · filed 2024-08-14 | -$55.90K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$392.02K 10-Q · filed 2023-05-12 | $60.00K derived: sum of 2 quarters · filed 2024-04-01 | $11.08K derived: sum of 3 quarters · filed 2024-04-01 | $22.45K derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-12-31 | $452.02K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $403.10K derived: sum of 2 quarters · filed 2024-04-01 | $414.47K derived: sum of 3 quarters · filed 2024-04-01 | $339.66K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$48.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$37.55K derived: sum of 2 quarters · filed 2023-11-13 | -$112.36K 10-Q · filed 2023-11-13 | -$327.99K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $11.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$63.44K 10-Q · filed 2023-08-14 | -$279.06K derived: sum of 3 quarters · filed 2023-08-14 | -$382.79K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$74.81K 10-Q · filed 2023-05-12 | -$290.44K derived: sum of 2 quarters · filed 2023-05-12 | -$394.17K derived: sum of 3 quarters · filed 2023-05-12 | -$450.63K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$215.63K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$319.35K derived: sum of 2 quarters · filed 2023-03-30 | -$375.81K derived: sum of 3 quarters · filed 2023-03-30 | -$520.41K 10-K · filed 2023-03-30 |
| 2021-09-30 | -$103.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$160.19K derived: sum of 2 quarters · filed 2022-11-14 | -$304.79K 10-Q · filed 2022-11-14 | -$254.25K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$56.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$201.06K 10-Q · filed 2022-08-11 | -$150.53K derived: sum of 3 quarters · filed 2022-08-11 | -$126.91K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$144.60K 10-Q · filed 2022-05-12 | -$94.06K derived: sum of 2 quarters · filed 2022-05-12 | -$70.44K derived: sum of 3 quarters · filed 2022-05-12 | -$1.44M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $50.54K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $74.16K derived: sum of 2 quarters · filed 2022-03-30 | -$1.30M derived: sum of 3 quarters · filed 2022-03-30 | $169.74K 10-K · filed 2022-03-30 |
| 2020-09-30 | $23.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.35M derived: sum of 2 quarters · filed 2021-11-12 | $119.20K 10-Q · filed 2021-11-12 | $118.99K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $95.58K 10-Q · filed 2021-08-13 | $95.37K derived: sum of 3 quarters · filed 2021-08-13 | $51.16K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $1.47M 10-Q · filed 2021-05-14 | $1.46M derived: sum of 2 quarters · filed 2021-05-14 | $1.42M derived: sum of 3 quarters · filed 2021-05-14 | |
| 2019-12-31 | -$205.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | -$44.42K derived: sum of 2 quarters · filed 2021-03-26 | -$12.88K 10-K · filed 2021-03-26 | |
| 2019-09-30 | -$44.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$12.67K 10-Q · filed 2020-11-13 | ||
| 2019-06-30 | $31.55K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |